The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Discovery World

FEBRUARY 24, 2023

For this evaluation, participants underwent an analytical treatment interruption (ATI) in their antiretroviral therapy (ART) for up to 24 weeks. The data show that a higher proportion of HTI+VES-treated participants remained off ART for the full 24 weeks.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Drug Discovery World

MARCH 30, 2023

This breakthrough marks the first of its kind in China and represents a significant milestone in innovative drug discovery pathways for cancer treatment. Personalised cancer vaccination is a potent strategy for triggering a broad-spectrum antitumour response.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus 52

Virus Immune Response Disease Clinical Trials 52

Drug Discovery World

MARCH 17, 2023

Researchers have shown for the first time that malfunctioning behaviour of a type of immune cell is linked to specific symptoms of Long Covid. Normally functioning monocytes, made in the bone marrow, would travel through the blood to the lungs where they surround and kill the virus and boost the immune response.

Immune Response 130

Immune Response Drugs Vaccine Virus 130

Drug Discovery World

AUGUST 2, 2022

Secondary endpoints will evaluate treatment efficacy, including progression-free and overall survival as well as any immune response to NeuroNova. . Our new platform uses stem cells like a ‘Trojan horse’ to shield the oncolytic viral particles from immune inactivation and deliver them to the tumor sites.

Trials 130

Trials FDA Immune Response Clinical Trials 130

Science Daily: Pharmacology News

OCTOBER 18, 2023

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months.

Therapies 74

Therapies Immune Response Research Virus 74

Drug Discovery World

JANUARY 17, 2024

5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL). The study examined viral evolution in eight Omicron variants to better understand how the virus has reacted since the introduction of vaccinations.

Virus 130

Virus Vaccine Immune Response Research 130

Drug Discovery World

JULY 26, 2022

BM: Calidi Therapeutics’ current pipeline consists of oncolytic virus-based immunotherapies potentiated by allogeneic stem cells and designed to treat patients for whom few, if any, effective treatment options exist. RA: How do oncolytic viruses work to attack cancer cells? Both therapies also had excellent safety profiles.

Virus 130

Virus Clinical Trials Therapies Trials 130

Drug Discovery World

JANUARY 22, 2024

In 2023, SandboxAQ announced a bio-pharma molecular simulation division, AQBioSim, to help biopharma and research institutions make treatment breakthroughs for patients. The company’s technology includes crypto-agile security, quantum sensing, and quantum simulation and optimisation.

Immune Response 147

Immune Response Vaccine Engineering Virus 147

Drug Discovery World

FEBRUARY 28, 2024

According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

The Pharma Data

MARCH 23, 2022

“When the COVID-19 pandemic started, our multidisciplinary research teams switched our investigations of other viruses and bacteria to focus on a potential treatment for what was then a challenging new virus for us,” says Children’s Center microbiologist Lori Jones-Brando, Ph.D., alone each year.

Virus 52

Virus Immune Response Research Treatment 52

PLOS: DNA Science

OCTOBER 12, 2023

Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases. Can they deliver healing genes without triggering an overactive immune response? In addition to high cost and small markets, patient responses haven’t been predictable.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Target Review

NOVEMBER 24, 2023

The use of nanoparticles, which are around the size of a virus particle, is a very promising delivery method for overcoming chemotherapy issues. La-Beck explained: “The thing that’s really attractive with using a nanoparticle in cancer treatments is that the nanoparticle is much larger than chemotherapy molecules.”

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

Drug Discovery World

APRIL 15, 2023

Details of the poster presentation are as follows: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042 – Justin A Kenkel, PhD Monday, April 17, 2023, 1.30pm – 5pm ET, Poster Board 11 2. antibody-drug conjugate, for the treatment of CLDN18.2-expressing

Virus 130

Virus Clinical Trials Trials Therapies 130

The Pharma Data

APRIL 15, 2022

These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group. The neutralizing GMT against the wild-type virus was 2153 (after three doses), compared to 335 after two doses.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

Drug Target Review

MARCH 26, 2024

Moreover, all the advances made in better understanding the underlying immune response serve other indications in immuno-oncology and auto-immune diseases where better treatments are still needed.

Vaccine 110

Vaccine Virus Immune Response Science 110

NIH Director's Blog: Drug Development

JUNE 30, 2020

A major one is: just how well do those particular antibodies neutralize the virus to fight off the infection and help someone recover from COVID-19? Fortunately, most people get better—but should the typical antibody response take the credit? Not surprisingly, all volunteers had produced antibodies in response to the virus.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The researchers saw no signs of the virus in the tissue samples, which they said may mean that the damage was not caused by the virus itself.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

The Pharma Data

MARCH 8, 2022

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. In the light of the further risk of pandemics in the future, however, there remains need for direct antiviral drugs and treatments.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . The company has already tested the treatment on 10 adults between the ages of 56-70, and 10 over 71. million.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

Drug Target Review

JUNE 1, 2023

La Jolla Institute for Immunology (LJI), US, scientists demonstrated how antibodies obtained from a clinical study participant attach to the SARS-CoV-2 spike protein and neutralise the virus. The vaccine prompts the body to produce the spike protein, which allows the immune system to develop antibodies against the real virus.

Virus 97

Virus Vaccine Immune Response Research 97

Drug Target Review

SEPTEMBER 11, 2023

This study, conducted using human cancer cells grown in a lab and mouse models mimicking human breast and lung cancer, revealed that the biomolecule treatment notably reduced tumour growth and increased survival rates. Tender elaborated that these results in immune cells ignoring the cancer rather than eliminating it, as they normally would.

Immune Response 116

Immune Response Research Engineering Virus 116

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus. Both attach to the spike of the virus at slightly different places.

Trials 52

Trials Immune Response Virus Vaccine 52

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. The Lancet 390 , 849-860 (2017). Nyberg WA, et al.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. There is a clear opportunity to repurpose some of these candidates for preventative/ prophylactic treatment for post-Covid-19 cognitive impairment.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

SEPTEMBER 29, 2020

Treatment is being developed by Australian biotech Ena Respiratory. A novel nasal spray treatment, being developed by Australian biotech Ena Respiratory, produced promising results against COVID-19 in an animal study performed by Public Health England (PHE) scientists. Source link.

Small Molecule 52

Small Molecule Immune Response Virus Treatment 52

Drug Target Review

FEBRUARY 7, 2024

We had built a machine learning classifier that has been trained to identify amino acid sequences that have the potential to mimic ‘host defense peptides’ from the human innate immune system. Such peptides play a critical role in the machinery for amplifying innate immune responses. This work can potentially help with that also.

RNA 69

RNA Virus Immune Response Engineering 69

Drug Discovery World

APRIL 3, 2023

The findings indicate that a drug compound, R805/CX-011, may modulate an important cell receptor in the body’s immune system, GP130, that signals when antibodies should attack a virus or infection.

Clinical Trials 130

Clinical Trials Trials FDA Approval Drugs 130

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

Though more study is needed, the researchers say the decoy therapy could potentially be delivered directly to the lungs through an inhaler and used alone or in combination with other COVID-19 treatments. The ACE2 drug candidate, which is soluble and degrades in the body, also proved ineffective in neutralizing the virus.

Virus 52

Virus Clinical Trials Engineering Immune Response 52

Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Pharma Data

SEPTEMBER 4, 2020

S, prevented severe clinical disease in Syrian golden hamsters when challenged with SARS-CoV-2, the virus that causes COVID-19 in people. The company also announced the end of development of pimodivir, an investigational antiviral treatment for influenza A infection. End of the line for pimodivir in flu. Source link.

Vaccine 52

Vaccine Immune Response Virus Disease 52

The Pharma Data

OCTOBER 28, 2020

. “We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. And, how can those structural differences serve as blueprints for promising new treatments to combat many potentially deadly viruses?

Virus 52

Virus Immune Response Clinical Trials Vaccine 52